Literature DB >> 14523886

Efficacy of alteplase thrombolysis for ED treatment of pulmonary embolism with shock.

Philippe Le Conte1, Ludovic Huchet, David Trewick, Céline Longo, Irshaad Vial, Eric Batard, Danielle Yatim, Marie Dominique Touzé, Denis Baron.   

Abstract

Our objective was to assess efficacy and tolerance of thrombolysis using 0.6 mg/kg of Alteplase in patients with massive pulmonary embolism defined as the association of a pulmonary embolism with shock. We retrospectively included 21 patients presenting with a massive pulmonary embolism confirmed by either scintigraphy or spiral computed tomography. Patients were treated on the basis of a standard rationale followed by thrombolysis with 0.6 mg/kg Alteplase over a period of 15 minutes. Hospital mortality, vital signs before and 2 hours after thrombolysis, and incidence of hemorrhagic events were recorded. Five patients (23.8%) died, 4 of these deaths occurred during the first 4 hours after hospital admission. Systolic and diastolic blood pressure (Sp02) were significantly improved 2 hours after the beginning of thrombolysis. Five minor hemorrhagic events occurred. This study demonstrates that for patients with pulmonary embolism and shock, a bolus treatment with Alteplase is potentially effective and well tolerated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14523886     DOI: 10.1016/s0735-6757(03)00098-6

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  2 in total

1.  Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism.

Authors:  Tyree H Kiser; Ellen L Burnham; Brendan Clark; P Michael Ho; Richard R Allen; Marc Moss; R William Vandivier
Journal:  Crit Care Med       Date:  2018-10       Impact factor: 7.598

2.  All contraindications to thrombolysis for life-threatening pulmonary embolus should be considered relative.

Authors:  Rachel M Mercer; Jordan S T Bowen; Richard J Armstrong
Journal:  BMJ Case Rep       Date:  2013-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.